Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome

Leukemia

Volumn 12, Issue SUPPL. 1, 1998, Pages

  Matthews, Dana C ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acute myelogenous leukemia; Monoclonal antibody; Myelodysplastic syndrome; Radioisotope

Indexed keywords

CALICHEAMICIN; CD33 ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CONFERENCE PAPER; HUMAN; IMMUNOTHERAPY; ISOTOPE LABELING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0031724897     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Jurcic JG, Caron PC, Scheinberg DA. Monoclonal antibody therapy of leukemia and lymphoma. Adv Pharmacol 1995;33:287-314.
2. Jurcic JG, Scheinberg DA. Monoclonal antibody therapy of myeloid leukemias. PPO Updates 1995;9:1-12.
3. Xu Y, Xu Q, Rosenblum MG, Scheinberg DA. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice. Leukemia 1996;10:321-326.
4. McGraw KJ, Rosenblum MG, Cheung L, Scheinberg DA. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol Immunother 1994;39:367-374.
5. Caron PC, Jurcic JG, Dumont L, Tyson D, Scheinberg DA. High-dose infusional humanized anti-CD33 M195: Prospects for treating minimal disease in myeloid leukemia. Blood 1996;88(suppl 1):218a (abstract 859).
6. Jurcic JG, DeBlasio A, Dumont L, Warrell Jr RP, Scheinberg DA. Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia (APL). Blood 1997;90(suppl 1):416a (abstract 1850).
7. Nicolaou KC, Pitsinos EN, Theodorakis EA, Saimoto H, Wrasidlo W. Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis. Chem Biol 1994;1:57-66.
8. Sievers EL, Appelbaum FA, Spielberger RT, Forman SJ, Flowers DA, Berger MS, Shannon-Dorcy K, Bernstein ID. Selective ablation of acute myeloid leukemia using an anti-CD33 calicheamicin immunoconjugate. Blood 1997;90(suppl 1):504a (abstract 2246).
9. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED, Bernstein ID. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992;54:829-833.
10. Jurcic JG, McDevitt MR, Sgouros G, Ballangrud A, Finn RD, Geerlings MW, Humm JL, Molinet R, Apostolidis C, Larson SM, Scheinberg DA. Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33). Blood 1997;90(suppl 1):504a (abstract 2245).
11. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1997;90(suppl 1):417a (abstract 1854).
12. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in match-related transplants for AML in first remission. Blood 1996;88(suppl 1):142a (abstract 556).